BiotechTube

Sevelamer Hydrochloride (Renagel®) + Calcium acetate (PhosLo® )

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Peritoneal Dialysis

Conditions

Peritoneal Dialysis, Chronic Kidney Disease

Trial Timeline

Dec 1, 2004 → Apr 1, 2006

NCT ID
NCT00196755

About Sevelamer Hydrochloride (Renagel®) + Calcium acetate (PhosLo® )

Sevelamer Hydrochloride (Renagel®) + Calcium acetate (PhosLo® ) is a phase 3 stage product being developed by Sanofi for Peritoneal Dialysis. The current trial status is completed. This product is registered under clinical trial identifier NCT00196755. Target conditions include Peritoneal Dialysis, Chronic Kidney Disease.

What happened to similar drugs?

3 of 6 similar drugs in Peritoneal Dialysis were approved

Approved (3) Terminated (1) Active (3)
✅ertapenemMerckApproved
✅Extraneal (7.5% icodextrin) Peritoneal Dialysis SolutionBaxterApproved
✅Icodextrin Peritoneal Dialysis Solution + Hypertonic Dextrose solutionBaxterApproved
🔄R744 + R744Chugai PharmaceuticalPhase 3
🔄roxadustatAstellas PharmaPhase 3
🔄PA21Kissei PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00196755Phase 3Completed

Competing Products

20 competing products in Peritoneal Dialysis

See all competitors
ProductCompanyStageHype Score
azenosertibZentalis PharmaceuticalsPhase 2
32
MCY-M11 + CyclophosphamideMaxCytePhase 1
11
R744 + R744Chugai PharmaceuticalPhase 3
40
roxadustatAstellas PharmaPhase 3
40
AbemaciclibEli LillyPhase 1
36
M200 (Volociximab) + Liposomal Doxorubicin + M200 (Volociximab) + M200 (Volociximab)AbbViePhase 1/2
32
Adavosertib + Paclitaxel + Carboplatin + Gemcitabine + PLDAstraZenecaPhase 2
35
Tremelimumab + OlaparibAstraZenecaPhase 1
21
ertapenemMerckApproved
43
Octreotide LAR + Octreotide (Immediate release) + methylprednisolone + PlaceboNovartisPhase 2
35
PA21Kissei PharmaceuticalPhase 3
40
PF-06873600 + Endocrine Therapy 1 + Endocrine Therapy 2PfizerPhase 1/2
24
Bevacizumab + Nivolumab + RucaparibBristol Myers SquibbPhase 2
39
IniparibSanofiPhase 2
35
nanoliposomal irinotecanIpsenPhase 1
26
Extraneal (7.5% icodextrin) Peritoneal Dialysis SolutionBaxterApproved
32
Anti-Adhesion ProductBaxterPhase 2
32
PioglitazoneBaxterPre-clinical
23
Icodextrin Peritoneal Dialysis Solution + Hypertonic Dextrose solutionBaxterApproved
47
RadspherinOncoinventPhase 2
32